英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：


请选择你想看的字典辞典：
单词字典翻译
kras查看　kras　在百度字典中的解释百度英翻中〔查看〕
kras查看　kras　在Google字典中的解释Google英翻中〔查看〕
kras查看　kras　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • Targeting KRAS mutations: orchestrating cancer evolution and . . . - Nature
    KRAS proteins are known for their intrinsic GTPase activity and are “the most mutated protein in cancer” 1 KRAS mutation is foundational to in vivo oncogenic transformation 2, 3 and is widely
  • KRAS-targeted therapies in cancer: novel approaches and overcoming . . .
    KRAS, once considered undruggable, has become actionable across specific alleles, with KRAS-G12C inhibitors now approved and next-generation approaches—including pan-KRAS pan-RAS inhibitors, targeted degraders and RNA-based strategies—progressing rapidly However, clinical benefit remains limited due to the frequent emergence of resistance Escape mechanisms include on-target secondary
  • What’s new in KRAS mutation research? | UT MD Anderson
    Although KRAS and its links to cancer were discovered decades ago, characteristics of its protein structure was thought to make it “undruggable ” That changed a few years ago when the Food and Drug Administration (FDA) approved covalent inhibitors of the KRAS G12C mutation, the drugs sotorasib and adagrasib, both of which were tested at MD Anderson
  • KRAS Inhibitors: Targeting the Undruggable Mutation in 2026 and Beyond
    Pan-KRAS and Pan-RAS Strategies To address multiple mutations simultaneously: Inhibitors like JAB-23E73 and BBO-11818 entered early clinical trials in 2025, showing broad activity against G12D V and others in preclinical models Revolution Medicines' pipeline (including elironrasib for G12C) emphasizes tri-complex mechanisms for enhanced potency
  • KRAS mutation: from undruggable to druggable in cancer
    In addition, patients with KRAS mutations usually have a poor response to current standard therapy 11 There has been an urgent and unmet need to target KRAS mutations in KRAS-driven cancer
  • What Is KRAS and Why Is It So Hard to Target in Cancer?
    Current KRAS G12C inhibitors in non-small cell lung cancer show response rates of about 30% to 40% and a median progression-free survival of around six months How should patients understand what these numbers mean in practical terms today? In practical terms, these numbers mean that a meaningful benefit is seen in a portion of patients
  • KRAS Mutations in Solid Tumors: Characteristics, Current Therapeutic . . .
    With KRAS lacking classical drug binding sites, the development of an inhibitor targeting KRAS mutations is extremely challenging, resulting in no breakthrough in KRAS-targeted therapy for a long time Traditionally, chemotherapy has been used for patients with KRAS-mutant lung cancer and other solid tumors
  • KRAS gene: MedlinePlus Genetics
    The KRAS gene provides instructions for making a protein called K-Ras that is part of a signaling pathway known as the RAS MAPK pathway Learn about this gene and related health conditions
  • KRAS Inhibitors (2026): The Complete Guide to Targeted Therapy . . .
    Today, KRAS is no longer a scientific dead end—it is one of the most actively targeted oncogenic drivers in modern precision medicine Multiple generations of KRAS inhibitors now exist, and treatment strategies are evolving from single-mutation targeting toward pan-RAS pathway control and combination therapy systems





中文字典-英文字典  2005-2009